Description: Vyant Bio, Inc. (“Vyant Bio” or “Company”) operates two wholly-owned subsidiaries, StemoniX and vivoPharm. The Company is executing on the integration of these two leading businesses to integrate human-powered scientific and technology-based systems and expertise with years of preclinical experience to de-risk and accelerate discovery and development of preclinical and clinical pipelines for biopharma partners as well as for the proprietary pipeline of the Company. StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate, and consistent, these human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. Through collaborations with drug discovery organizations, StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes custom human iPSC-derived disease models at large scale for high-throughput screening. With leading-edge iPSC technologies and data science, StemoniX is helping global institutions bring the most promising medicines to patients. vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm is focused on precision and translational medicine to drive drug discovery and novel therapies. vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. vivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities
Home Page: www.vyantbio.com
VYNT Technical Analysis
2 Executive Campus
Cherry Hill,
NJ
08002
United States
Phone:
201 479 1357
Officers
| Name | Title |
|---|---|
| Mr. John A. Roberts M.B.A., MBA | Pres, CEO & Director |
| Mr. Yung-Ping Yeh M.B.A., M.S., P.M.P. | Co-Founder & Director |
| Mr. Andrew D.C. LaFrence CPA, CPA | Chief Financial Officer |
| Dr. Robert Thomas Fremeau Jr., Ph.D. | Chief Scientific Officer |
| Dr. Robert J. Petcavich Ph.D. | Chief Science Advisor & Director |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.8871 |
| Price-to-Book MRQ: | 0.4142 |
| Price-to-Sales TTM: | 5.5207 |
| IPO Date: | 2013-04-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 34 |